Clinical Trials Browser

Has results × Pancreatic Neoplasms × pembrolizumab × Clear all

Pancreatic Neoplasms, Colorectal Neoplasms

NCT03797326 2026-05-04

LEAP-005

Parkinson Disease 4, Autosomal Dominant Lewy Body, Biliary Tract Neoplasms, Glioblastoma, Ovarian Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Triple Negative Breast Neoplasms

NCT05014776 2026-04-28

Study of CRS-207, Pembrolizumab, Ipilimumab, and Tadalafil in Metastatic Pancreatic Cancer

Phase 2 Completed

17 enrolled 8 charts

Gastrointestinal

Adenocarcinoma, Carcinoma, Pancreatic Neoplasms

NCT02648282 2026-03-13

Study With CY, Pembrolizumab, GVAX Pancreas Vaccine, and SBRT in Patients With Locally Advanced Pancreatic Cancer

Phase 2 Completed

58 enrolled 9 charts

Gastrointestinal

Pancreatic Neoplasms

NCT04332653 2026-03-09

NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors

Phase 1/2 Completed

215 enrolled 30 charts

BreastGastrointestinalGynecologicThoracic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Carcinoma, Non-Small-Cell Lung, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Thoracic Neoplasms, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT03727880 2026-02-04

Study of Pembrolizumab With or Without Defactinib Following Chemotherapy as a Neoadjuvant and Adjuvant Treatment for Resectable Pancreatic Ductal Adenocarcinoma

Phase 2 Completed

28 enrolled 11 charts

Gastrointestinal

Pancreatic Neoplasms

NCT03264404 2026-01-27

Azacitidine and Pembrolizumab in Pancreatic Cancer

Phase 2 Completed

36 enrolled 11 charts

Gastrointestinal

Pancreatic Neoplasms

NCT05070247 2026-01-22

A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors

Phase 1/2 Terminated

61 enrolled 29 charts

BreastGastrointestinalGenitourinaryHead & NeckOther solid neoplasmThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Kidney Neoplasms, Liver Neoplasms, Mesothelioma, Nasopharyngeal Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms

NCT05052723 2025-11-19

Cabozantinib and Pembrolizumab in Metastatic Pancreas

Phase 2 Completed

21 enrolled 12 charts

Gastrointestinal

Adenocarcinoma, Neoplasm Metastasis, Pancreatic Neoplasms

NCT04306900 2025-07-29

TTX-030 in Combination With Immunotherapy and/or Chemotherapy in Subjects With Advanced Cancers

Phase 1 Completed

185 enrolled 28 charts

GastrointestinalGenitourinaryThoracic

Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis, Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms

NCT03884556 2025-07-02

TTX-030 Single Agent and in Combination With Immunotherapy or Chemotherapy for Patients With Advanced Cancers

Phase 1 Completed

56 enrolled 19 charts

GastrointestinalGenitourinaryLymphoidThoracic

Urinary Bladder Neoplasms, Lung Neoplasms, Lymphoma, Neoplasms, Pancreatic Neoplasms

NCT04907851 2025-03-17

KEYNOTE-E86

Phase 2 Completed

45 enrolled 25 charts

Gastrointestinal

Biliary Tract Neoplasms, Pancreatic Neoplasms, Cholangiocarcinoma

NCT03058289 2025-02-27

IT-01

Phase 1/2 Completed

111 enrolled 21 charts

BreastGastrointestinalHead & NeckLymphoidSarcomaThoracic

Diabetes Mellitus, Insulin-Dependent, 12, Bile Duct Neoplasms, Breast Neoplasms, Carcinoma, Carcinoma, Squamous Cell, Colonic Neoplasms, Head and Neck Neoplasms, Liver Neoplasms, Lung Neoplasms, Lymphoma, Neoplasms, Pancreatic Neoplasms, Sarcoma

NCT03948763 2025-01-28

V941-001

Phase 1 Terminated

70 enrolled 18 charts

GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms

NCT03153410 2025-01-09

Pilot Study With CY, Pembrolizumab, GVAX, and IMC-CS4 (LY3022855) in Patients With Borderline Resectable Adenocarcinoma of the Pancreas

Phase EARLY_PHASE1 Completed

11 enrolled 14 charts

Gastrointestinal

Adenocarcinoma, Neoplasms, Pancreatic Neoplasms

NCT03006302 2024-10-08

Epacadostat, Pembrolizumab, and CRS-207, With or Without CY/GVAX Pancreas in Patients With Metastatic Pancreas Cancer

Phase 2 Completed

41 enrolled 14 charts

Gastrointestinal

Pancreatic Neoplasms

NCT03621982 2024-06-13

Study of ADCT-301 in Patients With Selected Advanced Solid Tumors

Phase 1 Terminated

78 enrolled 39 charts

BreastDermatologicGastrointestinalGenitourinaryGynecologicThoracic

Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Colonic Neoplasms, Esophageal Neoplasms, Fallopian Tube Neoplasms, Melanoma, Ovarian Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms, Triple Negative Breast Neoplasms

NCT04148937 2024-04-05

A Study of the CD73 Inhibitor LY3475070 Alone or in Combination With Pembrolizumab in Participants With Advanced Cancer

Phase 1 Completed

52 enrolled 21 charts

BreastDermatologicGastrointestinalGenitourinaryGynecologicThoracic

Carcinoma, Ovarian Epithelial, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Melanoma, Neoplasm Metastasis, Pancreatic Neoplasms, Triple Negative Breast Neoplasms

NCT02713529 2023-01-20

Safety and Efficacy Study of AMG 820 and Pembrolizumab Combination in Select Advanced Solid Tumor Cancer

Phase 1/2 Completed

117 enrolled 35 charts

GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Pancreatic Neoplasms, Colorectal Neoplasms

NCT03331562 2022-12-27

A SU2C Catalyst® Trial of a PD1 Inhibitor With or Without a Vitamin D Analog for the Maintenance of Pancreatic Cancer

Phase 2 Completed

24 enrolled 14 charts

Gastrointestinal

Pancreatic Neoplasms

NCT03723915 2022-10-05

Pembrolizumab and Pelareorep in Treating Patients With Advanced Pancreatic Cancer

Phase 2 Terminated

17 enrolled 14 charts

Gastrointestinal

Pancreatic Neoplasms

NCT03681951 2020-07-31

First-time-in-human (FTIH) Study of GSK3145095 Alone and in Combination With Other Anticancer Agents in Adults With Advanced Solid Tumors

Phase 2 Terminated

8 enrolled 24 charts

Gastrointestinal

Pancreatic Neoplasms

NCT02362048 2019-10-01

KEYNOTE144

Phase 2 Completed

77 enrolled 11 charts

Gastrointestinal

Pancreatic Neoplasms

Clinical Trials

Pembrolizumab and XL888 in Patients With Advanced Gastrointestinal Cancer

LEAP-005

Study of CRS-207, Pembrolizumab, Ipilimumab, and Tadalafil in Metastatic Pancreatic Cancer

Study With CY, Pembrolizumab, GVAX Pancreas Vaccine, and SBRT in Patients With Locally Advanced Pancreatic Cancer

NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors

Study of Pembrolizumab With or Without Defactinib Following Chemotherapy as a Neoadjuvant and Adjuvant Treatment for Resectable Pancreatic Ductal Adenocarcinoma

Azacitidine and Pembrolizumab in Pancreatic Cancer

A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors

Cabozantinib and Pembrolizumab in Metastatic Pancreas

TTX-030 in Combination With Immunotherapy and/or Chemotherapy in Subjects With Advanced Cancers

TTX-030 Single Agent and in Combination With Immunotherapy or Chemotherapy for Patients With Advanced Cancers

KEYNOTE-E86

IT-01

V941-001

Pilot Study With CY, Pembrolizumab, GVAX, and IMC-CS4 (LY3022855) in Patients With Borderline Resectable Adenocarcinoma of the Pancreas

Epacadostat, Pembrolizumab, and CRS-207, With or Without CY/GVAX Pancreas in Patients With Metastatic Pancreas Cancer

Study of ADCT-301 in Patients With Selected Advanced Solid Tumors

A Study of the CD73 Inhibitor LY3475070 Alone or in Combination With Pembrolizumab in Participants With Advanced Cancer

Safety and Efficacy Study of AMG 820 and Pembrolizumab Combination in Select Advanced Solid Tumor Cancer

A SU2C Catalyst® Trial of a PD1 Inhibitor With or Without a Vitamin D Analog for the Maintenance of Pancreatic Cancer

Pembrolizumab and Pelareorep in Treating Patients With Advanced Pancreatic Cancer

First-time-in-human (FTIH) Study of GSK3145095 Alone and in Combination With Other Anticancer Agents in Adults With Advanced Solid Tumors

KEYNOTE144